The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein

被引:0
|
作者
Keleti, J
Quezado, MM
Abaza, MM
Raffeld, M
Tsokos, M
机构
[1] NCI,HEMATOPATHOL SECT,PATHOL LAB,NIH,BETHESDA,MD 20892
[2] NCI,PEDIAT TUMOR BIOL ULTRASTRUCT PATHOL SECT,NIH,BETHESDA,MD 20892
来源
AMERICAN JOURNAL OF PATHOLOGY | 1996年 / 149卷 / 01期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
MDM2 gene overexpression has been implicated in the pathogenesis of human neoplasia via inhibition of the p53 tumor-suppressor function. To investigate the potential involvement of the MDM2 oncogene in the pathogenesis of childhood rhabdomyosarcoma (RMS), we studied MDM2 abnormalities in six RMS cell lines in correlation with the p53 status. Three showed overexpression of MDM2 mRNA and protein, one with concomitant MDM2 mRNA and protein, one with concomitant MDM2 gene amplification. All three lacked p53 mutation and expressed low levels of p53 mRNA but exhibited elevated p53 proteins. Double immunostaining revealed that the overexpressed MDM2 and p53 proteins were co-localized to the same cell nuclei. Furthermore, the two proteins were physically associated, as shown by co-immunoprecipitation and Western blot analysis. The half-life of the p53 protein was prolonged in the MDM2-overexpressing RMS cells. The extended half-life of the wild-type p53 protein and its complex formation with the elevated MDM2 suggest that the underlying mechanism for p53 protein accumulation in these cell lines is p53 stabilization by an overabundant MDM2 protein. The overexpressed MDM2 protein had a short half-life. The three remaining RMS cell lines exhibited low MDM2 mRNA and protein levels and carried p53 mutations. This study suggests that MDM2 overexpression represents an alternative mechanisms for p53 inactivation in a subset of childhood RMS without p53 mutations. The results further indicate that the elevated MDM2 protein is responsible for wild-type p53 protein accumulation via stabilization.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 50 条
  • [21] MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53
    Klein, Alyssa M.
    Biderman, Lynn
    Tong, David
    Alaghebandan, Bita
    Plumber, Sakina A.
    Mueller, Helen S.
    van Vlimmeren, Anne
    Katz, Chen
    Prives, Carol
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (44)
  • [22] THE MDM-2 ONCOGENE IS TRANSLOCATED AND OVEREXPRESSED IN A MURINE PLASMACYTOMA CELL-LINE EXPRESSING WILD-TYPE P53
    BERBERICH, S
    COLE, M
    ONCOGENE, 1994, 9 (05) : 1469 - 1472
  • [23] A MDM2 inhibitor achieves synergistic cytotoxicity with oncolytic adenoviruses on mesothelioma with the wild-type p53
    Thi Thanh Thao Nguyen
    Zhong, Boya
    Morinaga, Takao
    Kubo, Shuji
    Sekine, Ikuo
    Tada, Yuji
    Tatsumi, Koichiro
    Shimada, Hideaki
    Hiroshima, Kenzo
    Tagawa, Masatoshi
    CANCER SCIENCE, 2018, 109 : 960 - 960
  • [24] Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells
    Kraus, A
    Neff, F
    Behn, M
    Schuermann, M
    Muenkel, K
    Schlegel, J
    INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (06) : 930 - 934
  • [25] Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
    Landers, JE
    Cassel, SL
    George, DL
    CANCER RESEARCH, 1997, 57 (16) : 3562 - 3568
  • [26] Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells
    Geng, Qian-Qian
    Dong, Dan-Feng
    Chen, Nan-Zheng
    Wu, Yin-Ying
    Li, En-Xiao
    Wang, Jie
    Wang, Shao-Meng
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (06) : 1935 - 1942
  • [27] Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML
    Kucia-Tran, J.
    Bevan, L.
    Chessari, G.
    Fazal, L.
    Ferrari, N.
    Lyons, J.
    Saini, H.
    Wallis, N.
    Ward, G.
    Ahn, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S83 - S84
  • [28] The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network
    Mayo, LD
    Donner, DB
    TRENDS IN BIOCHEMICAL SCIENCES, 2002, 27 (09) : 462 - 467
  • [29] The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants
    Brown, DR
    Deb, D
    Frum, R
    Hickes, L
    Munoz, R
    Deb, S
    Deb, SP
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (03) : 449 - 459
  • [30] Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC)
    Ananthapadmanabhan, Varsha
    Frost, Thomas C.
    Soroko, Kara M.
    Knott, Aine
    Magliozzi, Brianna
    Gokhale, Prafulla C.
    Tirunagaru, Vijaya
    Doebele, Robert C.
    DeCaprio, James A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (10) : 2837 - 2837